Hoover Financial Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
$667K Buy
17,021
+2,688
+19% +$105K 0.12% 67
2021
Q1
$564K Buy
14,333
+166
+1% +$5.89K 0.11% 66
2020
Q4
$521K Sell
14,167
-747
-5% -$27.4K 0.13% 56
2020
Q3
$519K Buy
14,914
+137
+0.9% +$4.8K 0.17% 51
2020
Q2
$458K Buy
14,777
+117
+0.8% +$3.98K 0.18% 48
2020
Q1
$454K Sell
14,660
-211
-1% -$7.19K 0.25% 39
2019
Q4
$553K Sell
14,871
-2,655
-15% -$94.6K 0.27% 44
2019
Q3
$597K Buy
17,526
+190
+1% +$6.91K 0.53% 26
2019
Q2
$713K Buy
17,336
+735
+4% +$29.2K 0.66% 20
2019
Q1
$669K Hold
16,601
0.64% 20
2018
Q4
$687K Buy
+16,601
New +$689K 0.76% 19

Other funds holding PFE

Hoover Financial Advisors's PFE Position: Q2 2021 in Review

Hoover Financial Advisors increased its Pfizer (PFE) stake by 19% in Q2 2021, buying an estimated $105K and bringing the position to 17,021 shares worth $667K. The position accounts for 0.12% of the portfolio, ranked #67.

Hoover Financial Advisors first reported a position in PFE in Q4 2018 and has held it in 11 quarters since. The position peaked at $713K in Q2 2019. 2,732 funds tracked by Wall St. Rank hold PFE as of Q2 2021.

  • Hoover Financial Advisors held 17,021 shares of Pfizer worth $667K as of Q2 2021.
  • Hoover Financial Advisors bought 2,688 Pfizer shares in Q2 2021, an estimated $105K.
  • Pfizer made up 0.12% of Hoover Financial Advisors's portfolio in Q2 2021, its #67 holding.
  • Hoover Financial Advisors first reported a position in Pfizer in Q4 2018 and has held it in 11 quarters since.
  • Hoover Financial Advisors's Pfizer position peaked at $713K in Q2 2019.
  • 2,732 funds tracked by Wall St. Rank held Pfizer as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.